Abstract The landmark NUTRIREA‐2 and NUTRIREA‐3 trials compared the route and dose of nutrition, respectively, in critically ill patients with circulatory shock. The results of both trials support a “less‐is‐more” paradigm shift in the early acute phase of critical illness. In this review, the authors outline and appraise the results of the NUTRIREA‐2 and NUTRIREA‐3 trials, introduce the concept of identifying the “sweet spot” for nutrition dose based on severity of illness/nutrition risk and nutrition dose, and identify the unintended consequences of delivering full‐dose nutrition in sicker critically ill patients during the early acute phase of critical illness.
Clinical Practice Guidelines From the Association for the Advancement of Blood and Biotherapies (AABB): COVID-19 Convalescent Plasma